Page last updated: 2024-08-24

atorvastatin and Thrombophilia

atorvastatin has been researched along with Thrombophilia in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Artoni, A; Bergamaschini, L; Damanti, S; Lucchi, T; Mannucci, PM; Mari, D	1
Sillence, D; Tchan, M	1
Hansen, JB; Nordøy, A; Svensson, B	1
Dorner, GT; Joukhadar, C; Klein, N; Prinz, M; Schmetterer, L; Schrolnberger, C; Vukovich, T; Wolzt, M	1

Trials

2 trial(s) available for atorvastatin and Thrombophilia

Article	Year
Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:4 Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Factor VIIa; Fasting; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Kinetics; Male; Middle Aged; Peptide Fragments; Postprandial Period; Prothrombin; Pyrroles; Thrombophilia; Triglycerides	2003
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thrombosis and haemostasis, 2001, Volume: 85, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome	2001

Article

Year

Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia.

Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:4

Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Factor VIIa; Fasting; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Kinetics; Male; Middle Aged; Peptide Fragments; Postprandial Period; Prothrombin; Pyrroles; Thrombophilia; Triglycerides

2003

Thrombosis and haemostasis, 2001, Volume: 85, Issue:1

Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome

2001

Other Studies

2 other study(ies) available for atorvastatin and Thrombophilia

Article	Year
A thrombotic storm. Internal and emergency medicine, 2017, Volume: 12, Issue:1 Topics: Aged; Alprazolam; Amines; Amputation, Surgical; Atorvastatin; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Methicillin-Resistant Staphylococcus aureus; Thrombophilia; Ticlopidine; Venous Insufficiency; Venous Thrombosis	2017
Fabry disease and Factor V Leiden: a potent vascular risk combination. Internal medicine journal, 2011, Volume: 41, Issue:5 Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defibrillators, Implantable; Drug Therapy, Combination; Enzyme Replacement Therapy; Fabry Disease; Factor V; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metoprolol; Middle Aged; Perindopril; Pyrroles; Quality of Life; Recurrence; Sequence Deletion; Stents; Stroke; Stroke Rehabilitation; Thrombophilia; Warfarin	2011

Article

Year

A thrombotic storm.

Internal and emergency medicine, 2017, Volume: 12, Issue:1

Topics: Aged; Alprazolam; Amines; Amputation, Surgical; Atorvastatin; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Methicillin-Resistant Staphylococcus aureus; Thrombophilia; Ticlopidine; Venous Insufficiency; Venous Thrombosis

2017

Fabry disease and Factor V Leiden: a potent vascular risk combination.

Internal medicine journal, 2011, Volume: 41, Issue:5

Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defibrillators, Implantable; Drug Therapy, Combination; Enzyme Replacement Therapy; Fabry Disease; Factor V; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metoprolol; Middle Aged; Perindopril; Pyrroles; Quality of Life; Recurrence; Sequence Deletion; Stents; Stroke; Stroke Rehabilitation; Thrombophilia; Warfarin

2011